Whats New Out There
- Sort by:
- Date
- Alphabetical Order
Statins improve outcome from optic neuritis in people with MS
A randomised controlled trial has shown administration of a cholesterol-lowering drug (simvastatin) significantly improved the outcome for people with MS having an attack of optic neuritis Read more >Summary newsletter of vitamin D in MS from University of Wisconsin
Professor Colleen Hayes, Professor of Biochemistry at the University of Wisconsin, summarises recent developments in vitamin D for people with MS Read more >Problems for the oral MS drugs
The drug companies manufacturing the new oral drugs for MS, cladribine (Movectro) and fingolimod (Gilenya), have run into trouble getting their drugs approved and subsidised Read more >Large genetic study on MS breaks new ground
A large international effort in analysing the genome of thousands of people with MS has found many new genes influencing MS development Read more >Yet more evidence of the protective effect of sun exposure in preventing MS progression
Researchers from Baltimore have added to the evidence base behind sun exposure as a preventive factor in slowing MS progression Read more >Weight training improves quality of life and fatigue in MS
Researchers at La Trobe University in Victoria, Australia, show that gym training with weights for people with MS improves quality of life and fatigue Read more >Belgian review article outlines vascular abnormalities in MS
A new review published in Lancet Neurology outlines the various vascular abnormalities that are associated with MS, but finds little evidence of a causative role for CCSVI Read more >People with MS should avoid yellow fever vaccination
Vaccinations can be a cause for concern for people with MS; this study shows that yellow fever vaccination can markedly worsen relapse rate Read more >Endocrine Society Taskforce publishes new guidelines for vitamin D supplementation
After the Institute of Medicine's alarmist suggestions limiting the upper limit of vitamin D supplementation to 4,000IU a day, this new Clinical Practice Guideline for endocrinologists provides far more reasonable evidence-based recommendations Read more >Return of inflammatory activity after Tysabri not prevented by steroids and Copaxone
A Spanish study has shown that the well-known return of inflammatory activity after a course of Tysabri is stopped was not prevented with 3 monthly doses of steroids and Copaxone. Read more >